Bruce Wendel - 27 Jan 2023 Form 4 Insider Report for GT Biopharma, Inc. (GTBP)

Reporting relationship: Director
Issuer ticker: GTBP
Reported as of: 27 Jan 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 Feb 2023, 05:01:27 UTC
Prior SEC filing: 19 Jul 2022
Next SEC filing: 16 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Bruce Wendel

Key filing fact

Bruce Wendel filed Form 4 for GT Biopharma, Inc. (GTBP) on 01 Feb 2023.

Key facts

This page summarizes Bruce Wendel's Form 4 filing for GT Biopharma, Inc. (GTBP).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 01 Feb 2023, 05:01.

Change

Previous filing in this sequence was filed on 19 Jul 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GTBP transaction Derivative

Option to purchase Common Stock

Award

Transaction value: $0
Shares: +500,000
Change %
Price: $0.000000
Shares after: 500,000
Date: 27 Jan 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 500,000
Exercise price: $0.8370
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

1/12th of the shares vest on the monthly anniversary of January 1, 2023 until fully vested, subject to full acceleration in the event the reporting person is not re-elected to the board of directors or is removed from the board of directors other than for misconduct.